Investigating how muscimol can prevent a specific type of cell death
Official title: Mechanism of Muscimol as a Novel Pyroptosis Inhibitor
Funded at University of Washington · NIH-10877184 · Data updated 2026-11-12
This study is looking at how a compound called muscimol can help stop a type of harmful cell death linked to inflammation, which could lead to new treatments for serious health issues caused by too much inflammation.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $233,250 |
| NIH project number | 5R21AI178367-02 |
| Project ID | NIH-10877184 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from conditions associated with excessive inflammation and pyroptosis, such as stroke or cardiac infarction.
✕Less likely to help
Patients with conditions unrelated to pyroptosis or those not experiencing significant inflammatory responses may not benefit from this research.
What this research studies
This research explores the mechanism by which muscimol, a compound known for its effects on GABA receptors, can inhibit pyroptosis, a form of inflammatory cell death linked to various serious health conditions. The study aims to understand how muscimol prevents the rupture of cell membranes during pyroptosis and to identify new analogs of muscimol that may have stronger effects. By examining the interactions of muscimol with specific proteins involved in this process, the research seeks to uncover potential therapeutic targets for treating diseases associated with excessive inflammation and cell death.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that reduce inflammation and cell death in various diseases.
How similar studies have gone: While the specific approach of using muscimol as a pyroptosis inhibitor is novel, related research has shown promise in targeting cell death pathways for therapeutic purposes.
Where this research is happening
-
University of Washington
Seattle, United States Active
Researchers
- Principal investigator: Fink, Susan Leilani — University of Washington
- Study coordinator: Fink, Susan Leilani
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.